NR1H4 and atherosclerosis: In humans, this includes pathways clustering around IL-17 signaling, driven by the upregulation of CXCL1, IL-8 and CSF3, and atherosclerosis-associated pathways (i.e. atherosclerosis signaling, LXR/RXR activation, FXR\RXR activation), driven by the upregulation of apolipoprotein E (APOE) and C2 (APOC2).